Celltrion to Present New Analyses of ZYMFENTRA® (infliximab-dyyb) in Crohn’s Disease and Ulcerative Colitis at ACG 2026
Celltrion is presenting new analyses of ZYMFENTRA for treating Crohn’s disease and ulcerative colitis at ACG 2026. Data indicates favorable outcomes when switching to subcutaneous infliximab after intravenous treatment. This remains true regardless of the patient's prior antibody status. The study focused on adults with moderate to severely active conditions. Late-breaking analysis showed higher rates of clinical remission for patients with ileum-dominant Crohn’s disease. Subcutaneous administration showed improved endoscopic outcomes compared to intravenous options.
New data show favorable outcomes with subcutaneous infliximab following intravenous infliximab interruption, regardless of prior antibody status, in adult patients with moderate to severely active Crohn’s disease and ulcerative colitis Late-breaking analysis shows significantly higher rates of clinical remission and improved endoscopic outcomes with subcutaneous versus intravenous infliximab in patients with ileum-dominant Crohn’s disease JERSEY […]